(NASDAQ: FBLG) Fibrobiologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.08%.
Fibrobiologics's earnings in 2026 is -$18,680,000.On average, 4 Wall Street analysts forecast FBLG's earnings for 2026 to be -$15,089,185, with the lowest FBLG earnings forecast at -$14,497,452, and the highest FBLG earnings forecast at -$15,532,985. On average, 4 Wall Street analysts forecast FBLG's earnings for 2027 to be -$7,863,378, with the lowest FBLG earnings forecast at -$7,555,010, and the highest FBLG earnings forecast at -$8,094,654.
In 2028, FBLG is forecast to generate -$6,163,188 in earnings, with the lowest earnings forecast at -$5,921,495 and the highest earnings forecast at -$6,344,458.